Translational precision medicine: an industry perspective

被引:0
作者
Dominik Hartl
Valeria de Luca
Anna Kostikova
Jason Laramie
Scott Kennedy
Enrico Ferrero
Richard Siegel
Martin Fink
Sohail Ahmed
John Millholland
Alexander Schuhmacher
Markus Hinder
Luca Piali
Adrian Roth
机构
[1] Novartis Institutes for BioMedical Research,Department of Pediatrics I
[2] University of Tübingen,undefined
[3] Novartis Institutes for BioMedical Research,undefined
[4] Novartis Precision Medicine,undefined
[5] Reutlingen University,undefined
[6] Roche Innovation Center Basel,undefined
来源
Journal of Translational Medicine | / 19卷
关键词
Translational medicine; Precision medicine; Drug development; Biomarkers; Multi-omics; Modeling; Artificial intelligence; Pharmaceutical industry; Digital biomarkers; Companion diagnostics;
D O I
暂无
中图分类号
学科分类号
摘要
In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective.
引用
收藏
相关论文
共 654 条
[1]  
Paul SM(2010)How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat Rev Drug Discov 9 203-214
[2]  
Mytelka DS(2014)Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework Nat Rev Drug Discovery 13 419-431
[3]  
Dunwiddie CT(2018)Drug development in the era of precision medicine Nat Rev Drug Discov 17 183-196
[4]  
Persinger CC(2019)Are innovation and new technologies in precision medicine paving a new era in patients centric care? J Transl Med. 17 114-173
[5]  
Munos BH(2015)Bench-to-bedside; clinical and translational research; personalized medicine; precision medicine-what's in a name? Clin Transl Sci 8 171-1413
[6]  
Lindborg SR(2020)The evidence landscape in precision medicine Sci Transl Med. 12 eaaw7745-456
[7]  
Cook D(2019)Translational genomics and precision medicine: moving from the lab to the clinic Science 365 1409-842
[8]  
Brown D(2018)Translating translation Nat Rev Drug Discov 17 455-171
[9]  
Alexander R(2008)Translational research: crossing the valley of death Nature 453 840-91
[10]  
March R(2011)Bridging the translation gap - new hopes, new challenges Fund Clin Pharmacol 25 163-99